Scholarlink

<p>February, 2026 is the 40th anniversary of the 1st publication of rapid recovery of bone marrow function after high-dose chemotherapy and infusion of an autologous blood- rather than a bone-marrow-derived graft. The recipient, a man with advanced Burkitt lymphoma, is in remission and alive. In the next 40 years transplants of blood-derived progenitor cells have become the most common graft for auto- and allotransplants. The rapid hematopoietic recovery after blood cell-derived grafts is associated with fewer short-term complications and better outcomes in many settings compared with bone marrow-derived grafts but may be associated with more graft-<i>versus</i>-host disease (G<i>v</i>HD) after allotransplants. Using blood-derived grafts also reduced costs, enabled the development of cell-based immune therapy and in vitro manipulation of blood-derived cells for gene and chimeric antigen receptor (CAR)-T-cell therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blood cell-derived transplants at 40

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月14日

查看全文
  • Anthony D. Ho,
  • Peter Dreger,
  • Christopher Juttner,
  • Robert Peter Gale

摘要

February, 2026 is the 40th anniversary of the 1st publication of rapid recovery of bone marrow function after high-dose chemotherapy and infusion of an autologous blood- rather than a bone-marrow-derived graft. The recipient, a man with advanced Burkitt lymphoma, is in remission and alive. In the next 40 years transplants of blood-derived progenitor cells have become the most common graft for auto- and allotransplants. The rapid hematopoietic recovery after blood cell-derived grafts is associated with fewer short-term complications and better outcomes in many settings compared with bone marrow-derived grafts but may be associated with more graft-versus-host disease (GvHD) after allotransplants. Using blood-derived grafts also reduced costs, enabled the development of cell-based immune therapy and in vitro manipulation of blood-derived cells for gene and chimeric antigen receptor (CAR)-T-cell therapies.